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ABSTRACT
Objectives Ending HIV by 2030 is a global priority. Achieving 
this requires alternative HIV testing strategies, such as HIV 
self- testing (HIVST) to reach all individuals with HIV testing 
services (HTS). We present the results of a trial evaluating 
the impact of community- based distribution of HIVST in 
community and facility settings on the uptake of HTS in rural 
and urban Zambia.
Design Pair- matched cluster randomised trial.
Methods In catchment areas of government health facilities, 
OraQuick HIVST kits were distributed by community- based 
distributors (CBDs) over 12 months in 2016–2017. Within 
matched pairs, clusters were randomised to receive the 
HIVST intervention or standard of care (SOC). Individuals 
aged ≥16 years were eligible for HIVST. Within communities, 
CBDs offered HIVST in high traffic areas, door to door and at 
healthcare facilities. The primary outcome was self- reported 
recent testing within the previous 12 months measured using 
a population- based survey.
Results In six intervention clusters (population 148 541), 
60 CBDs distributed 65 585 HIVST kits. A recent test was 
reported by 66% (1622/2465) in the intervention arm 
compared with 60% (1456/2429) in SOC arm (adjusted risk 
ratio 1.08, 95% CI 0.94 to 1.24; p=0.15). Uptake of the HIVST 
intervention was low: 24% of respondents in the intervention 
arm (585/2493) used an HIVST kit in the previous 12 months. 
No social harms were identified during implementation.
Conclusion Despite distributing a large number of HIVST 
kits, we found no evidence that this community- based HIVST 
distribution intervention increased HTS uptake. Other models 
of HIVST distribution, including secondary distribution and 
community- designed distribution models, provide alternative 
strategies to reach target populations.
Trial registration number  ClinicalTrials. gov Registry 
(NCT02793804).
INTRODUCTION
HIV testing services (HTS) are the gateway 
to HIV prevention and treatment services. 
Without increased coverage of HTS, global 
treatment and viral load suppression targets 
are unlikely to be met. Over the past three 
decades, there has been considerable scale- up 
of HTS in sub- Saharan Africa. At the end of 
2015, the Joint United Nations Programme 
on HIV and AIDS estimates indicated that 
approximately 23% of all people living with 
HIV (PLHIV) in East and Southern Africa 
Key questions
What is already known?
 ► HIV testing coverage remains low in many popu-
lations in Southern Africa, and new strategies are 
needed to increase testing uptake particularly in 
settings and among populations where the number 
of people with undiagnosed HIV and new infections 
is high.
 ► HIV self- testing (HIVST) is acceptable in many pop-
ulations and can be a tool for increasing access to 
testing.
What are the new findings?
 ► After 12 months of a pragmatic HIVST distribution 
programme in communities in rural and urban 
Zambia, we found no evidence of an increase in pop-
ulation testing coverage in the general adult popula-
tion, among men, or among young people.
 ► In intervention areas, many people had not heard of 
HIVST or seen an HIVST community- based distribu-
tor in their community, suggesting that the interven-
tion may not have reached all population members.
What do the new findings imply?
 ► When new HIV testing strategies are implemented, 
rigorous monitoring and evaluation of activities in 
real time, with appropriate targeting to promote the 
identification of new testers and populations less 
likely to otherwise test, are necessary to ensure that 
the intervention reaches the target population.
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were unaware of their status. However, at the end of 2018, 
this figure was 15%.1 2 In Zambia, the 2016 Population- 
Based HIV Impact Assessment (ZAMPHIA) survey found 
annual incidence of HIV was around 0.67%, with around 
47 000 new cases of HIV in adults expected each year cite.3 
However, only 42.0% of women and 34.7% of men aged 
15–59 years had tested for HIV in the last 12 months.3 
Insufficient reach of HTS persists in Zambia despite 
substantial changes to local and international HIV testing 
guidelines over the past 15 years,4–7 and is likely impeding 
uptake of HIV treatment and prevention services among 
those who need them.
To increase HIV testing coverage, alternative strategies 
for delivering HTS are needed, particularly in settings 
and among populations where the number of people 
with undiagnosed HIV and new infections is high. HIV 
self- testing (HIVST), whereby an individual tests them-
selves and interprets the result in private, is one option 
for scaling up HTS, and is recommended by the WHO as 
a tool for increasing HIV testing uptake.8 HIVST is partic-
ularly promising for reaching population subgroups 
with limited access to standard HTS, including men and 
adolescents.9–13 Various HIVST distribution strategies 
have been shown to increase uptake of HTS, including 
providing HIVST kits to pregnant women to reach their 
male partners, facility- based distribution, and door to 
door and distribution through social networks.12 14 15 
HIVST is also an acceptable way to increase HIV testing 
uptake and frequency among key populations, including 
female sex workers16 17 and men who have sex with men.18
The UNITAID/PSI STAR (HIV Self- Testing AfRica) 
project was established to evaluate whether HIVST could 
increase HIV testing and support access to HIV care, 
treatment and prevention services in Africa, particu-
larly among men and adolescents.19 20 This study reports 
the results of a pragmatic cluster randomised trial to 
investigate the impact of HIVST when distributed by 
community- based distributors (CBDs) in Zambia.
METHODS
Trial design and participants
We conducted a pair- matched cluster randomised trial of 
distribution of oral HIVST kits via CBDs. HIVST distribu-
tion was managed by the Society for Family Health (SFH) 
in Zambia. Clusters consisted of the catchment areas of 
health facilities in four districts in Zambia: Lusaka (two 
clinics, urban), Choma (four clinics, two urban and two 
rural), Kapiri Mposhi (four clinics, two urban and two 
rural) and Ndola (two clinics, urban). Selection of clus-
ters was purposive and completed after consultation with 
the District Health Offices. Matching of the clusters was 
based on district and, within districts with four clusters, 
on distance from the clinic to the District Health, avail-
ability of antiretroviral therapy (ART) and HTS at the 
facility, and catchment population size. Total population 
in these clusters in 2010 ranged from 7933 to 58 246.21 
Within clusters, all residents aged 16 years and older were 
eligible to receive HIVST kits. The protocol for this study 
has been published elsewhere.22 There were no impor-
tant changes to the methods after the trial began.
Data collection
Household survey data
We used population- based cross- sectional survey data to 
assess the impact of the HIVST intervention. Intervention 
roll- out was staggered. The endline survey was completed 
at least 12 months after implementation commenced in 
each matched cluster pair, with the first clusters receiving 
the endline survey in October 2017 and the last in 
January 2018. A baseline survey was also conducted to 
assess balance on important cluster characteristics before 
the intervention began.
Sampling was conducted differently in rural and urban 
clusters. In rural clusters, we randomly selected standard 
enumeration areas defined by the Central Statistical 
Office and all households in these areas were approached 
to participate in the survey. In urban clusters, standard 
enumeration areas were subdivided into smaller blocks 
of 20–30 households. Blocks were randomly numbered 
and the first 12 were selected for data collection. Random 
sampling of blocks was done separately for baseline and 
endline surveys. Trained survey enumerators collected 
data using electronic data collection devices. A random 
20% subsample of participants were asked an extended 
survey with additional questions on stigma, social harms 
and intimate partner violence (IPV).
At the household, survey enumerators sought permis-
sion from the head of household or representative to 
the head of the household to administer the household 
survey. Individual written informed consent was obtained 
from participants willing to complete an individual ques-
tionnaire. No return visits were conducted for eligible 
individual household members absent at the time of the 
household visit.
ART data
Data on the number of individuals initiating ART in 
each month before and during the intervention were 
collected from health facility databases by research staff. 
For all health facilities, we had at least 5 months of data 
prior to the start of intervention, and at least 11 months 
of data during the intervention period.
Programme data
Throughout the intervention period, CBDs and imple-
mentation supervisors from SFH recorded the number 
of HIVST kits distributed in each of the six intervention 
clusters by all CBDs. Data were available on the number 
of HIVST kits distributed by sex, age and to first- time 
testers.
The HIVST intervention
The HIVST intervention was delivered at cluster level. 
In the six clinic catchment areas randomly allocated to 
receive the HIVST intervention, HIVST kits were distrib-
uted by CBDs using a pragmatic distribution strategy, 
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with CBDs distributing HIVST under typical program-
matic conditions with limited researcher input. CBDs 
were trained on strategies for distribution. HIVST kits 
were also distributed by one distributor in each health 
facility. Within the community, CBDs went door to door 
distributing HIVST kits to residents. They also distrib-
uted HIVST kits to people found in high- density areas, 
such as markets or bus stops. In three of the six clusters, 
trained voluntary medical male circumcision (VMMC) 
promoters also distributed HIVST kits. There was no limit 
to the number of HIVST kits available in each cluster.
Eligible individuals (≥16 years) were offered HIVST 
kits, and were able to receive one kit per CBD visit for 
their own use. Individuals were given a package consisting 
of an OraQuick HIV Self- Test labelled with a unique 
barcode, manufacturer’s instructions for use translated 
into local language, a self- completed referral card for 
linkage to post- test services and an envelope for returning 
the kit after use. They were also given demonstrations of 
how to use kits, read and interpret results. Participants 
were encouraged to return used kits to boxes located in 
the community and at the local health facility. Demand 
generation for HIVST was conducted in HIVST interven-
tion areas, and included monthly drama performances 
and announcements through public address systems and 
radios; and semimonthly distribution of fliers, brochures 
and posters. At the beginning of the intervention period, 
CBDs and VMMC mobilisers were paid a monthly stipend 
(US$83 for CBDs and facility- based distributors and 
US$50 for VMMC mobilisers). However, in March 2017 
this was changed to a pay- for- performance structure. 
After this point, CBDs and VMMC mobilisers were incen-
tivised based on the number of HIVST kits distributed 
and returned (US$0.56/distributed kit and US$0.28/
used kit returned).
HIVST implementation was staggered across clus-
ters, with implementation beginning in Lusaka in 
September 2016, Choma in October 2016, Kapiri Mposhi 
in December 2016 and Ndola in January 2017. HIVST 
distribution continued for at least 1 year in each cluster. 
In clusters randomised to standard of care (SOC), clus-
ters continued to receive HTS as provided by the health 
facility and other providers within each cluster.
Primary and secondary outcomes
The primary outcome was self- reported recent HIV 
testing, defined as testing for HIV in the 12 months 
prior to the date of the endline survey. The denomi-
nator included all individuals aged 16 years or older who 
consented to participate in the survey and had no missing 
data on whether they ever HIV tested. The numerator 
included individuals who reported one or more HIV tests 
in the 12 months prior to the survey.
Secondary outcomes included:
 ► HIV testing within 12 months after the intervention 
start date in each cluster. This outcome was included 
to aid the comparability of results of this cluster 
randomised trial with a similar trial in Malawi using 
this outcome.23
 ► Ever tested for HIV, which was chosen to highlight 
possible improvements in accessing previously 
untested populations using HIVST.
 ► Self- reported current ART use.
 ► Men circumcised in the last 12 months.
 ► ART initiation at clinic during the intervention period. 
Apart from ART initiation, which was collected using 
clinic data, all outcomes were based on individual 
self- report. Outcomes were measured at cluster level.
Process indicators and population assessment of harms and 
benefits
A community- based social harms reporting system was 
implemented in both HIVST and SOC areas. House-
hold survey data also included process indicators on the 
distribution of HIVST and on possible harmful outcomes 
related to the HIVST intervention, including experience 
of IPV,24 stigma,25 26 self- reported forced HIV testing and 
forced disclosure of results.
Sample size calculation
The sample size was calculated using standard methods 
for cluster randomised trials27 and assumed 80% power 
to detect a 50% relative increase in the proportion of 
individuals self- reporting a recent HIV test to 75%, with 
95% confidence and cluster coefficient of variation (k) of 
0.2. Using 2013–2014 Demographic and Health Surveys 
data, baseline levels for individuals tested in the last 12 
months were estimated to be 29% among men and 57% 
among women; we assumed a baseline recent HIV testing 
prevalence of 50% for the sample size calculation. For 
a two- sample comparison of matched proportions across 
six pairs of matched communities, we estimated that it 
would be necessary to recruit around 400 respondents 
per community, or 4800 respondents in total.
Randomisation and blinding
Within matched pairs, clusters were randomised 1:1 to 
receive either the HIVST intervention or SOC. Stata 
V.15.1 (College Station, Texas, USA) was used by BH to 
generate the random allocation sequence.
Cluster- level consent was obtained from the district 
medical office, management at each health facility and 
the neighbourhood health committees representing 
community members. Sensitisation activities were 
conducted in all communities before starting the study.
Due to the nature of the intervention, it was not possible 
to mask study participants or CBDs to intervention status. 
Survey and clinic data were collected by data collectors 
recruited and trained independently of SFH. Investiga-
tors were masked to allocation until after analysis of the 
primary outcome was complete.
Statistical methods
Analyses were conducted using standard methods for the 
analysis of a pair- matched cluster randomised trial with 
small number of clusters.27 Analyses were completed 
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by intention- to- treat, using cluster- level summaries and 
according to a prespecified analysis plan.
Baseline data were collected to assess balance across key 
characteristics associated with the outcome, including 
baseline recent and ever HIV testing, self- reported HIV 
status, and sociodemographic factors including age and 
sex. We used baseline data to identify imbalances across 
arms by age, sex and assets index. As these covariates 
were unlikely to have been affected by the intervention, 
we adjusted the analysis using values for these covariates 
measured at endline. At baseline, clusters were balanced 
by recent and ever HIV testing.
For unadjusted analyses, risk ratios (RRs) for each arm 
were calculated as geometric mean of cluster- level RRs, 
and a paired t- test used to calculate p values. For adjusted 
analyses, a two- stage process was used to adjust for imbal-
ances across arms. Prespecified subgroup analyses were 
conducted to determine whether the effect of the inter-
vention on the primary outcome is modified by sex, age 
(younger than 25 years; 25 years and older) and educa-
tional attainment.28
A separate analysis was undertaken to estimate any 
impact on monthly ART uptake at clinics by arm, using 
clinic- level data on the number of ART initiations in each 
month before and during the implementation period. 
For this analysis, the denominator was the overall popula-
tion of the clinic catchment area estimated using census 
data.21 Ordinary least squares regression was used to esti-
mate the effect of the intervention on logged number of 
ART initiations per month per 1000 population, and the 
regression model adjusted for clinic pair and total logged 
ART initiations per 1000 in the 5–10 months prior to the 
intervention start date.
All analyses were conducted using Stata V.15.1 
and adhere to Consolidated Standards of Reporting 
Trials reporting guidelines for the reporting of cluster 
randomised trials.29
Process evaluation
In addition to the analysis of impact, we conducted a 
retrospective quantitative process evaluation using survey 
and programme data to understand delivery and reach 
of the HIVST intervention.30 To guide the process evalua-
tion, we developed a simple framework of how the inter-
vention was expected to have an impact on the recent 
HIV testing (online supplemental figure 1).
Patient and public involvement
Community sensitisation meetings were conducted 
before the beginning of data collection, and forma-
tive research was conducted among key stakeholders 
to assess the acceptability of HIVST distribution in the 
community. A social harms reporting system including 
CBDs, local health clinics and traditional leaders was 
established as part of the trial. Community members 
were not involved in the research design or analysis of 
data.
RESULTS
The effect of the HIVST intervention on recent HIV testing
Twelve pair- matched clusters were randomised (figure 1). 
The total population in the study area was 308 822, with a 
median population of 15 465 per cluster (range: 7673–58 
246). At baseline, self- reported HIV prevalence was 8.4% 
(42/500) in the HIVST intervention arm and 8.3% 
(44/528) in the SOC arm, and recent testing coverage 
was 63.3% (1457/2272) in the HIVST arm and 64.1% 
(1496/2364) in SOC arm (table 1). The endline survey 
included 5005 participants. Participation in the endline 
survey was similar across arms, with 60.1% (2528/4202) 
of eligible household members participating in interven-
tion arm and 61.5% (2477/4027) in SOC arm. Partici-
pant characteristics were balanced across arms, though 
slightly more respondents in the SOC arm were in the 
lowest assets quintile. Across both arms, survey participa-
tion was higher among women than men. In both arms, 
2.2% of survey respondents did not provide information 
on HIV testing history and were omitted from the primary 
analysis (56/2528 in intervention and 55/2477 in SOC).
At endline, 65.8% (1626/2472) of respondents in the 
HIVST arm had recently tested compared with 60.0% 
(1452/2422) in the SOC arm, with no evidence of a differ-
ence between arms (adjusted RR: 1.08, 95% CI: 0.94 to 
1.25; p=0.224; table 2). There was no evidence of a differ-
ence between arms in any secondary outcomes (table 2). 
Subgroup analyses showed no statistical evidence for 
differences in recent testing by arm by respondent sex, 
age or education (online supplemental table 1).
Delivery of the HIVST intervention
The intervention was delivered in facilities and the 
community in all six intervention clusters. SFH trained 
60 CBDs to distribute HIVST kits across these six clus-
ters, with 12 CBDs per cluster in urban areas and 8–10 
per cluster in rural areas (table 3). CBDs distributed 
65 585 HIVST kits during the intervention; of these, 
53 626 (82%) were distributed in the community and the 
remainder in health facilities (8378; 13%) or by VMMC 
mobilisers (3581; 5%). The number of HIVST distrib-
uted per capita varied across clusters. The percentage 
of HIVST kits distributed to men ranged from 45.2% 
(3985/8823) to 56.0% (1384/20 322), and distribution 
to first- time testers ranged from 10.7% (696/6487) to 
29.1% (803/1768).
Reach of the HIVST intervention
Relative to the SOC arm, more individuals in the inter-
vention arm reported that they had seen a CBD in their 
community, had a CBD come to their household, and had 
ever or recently self- tested for HIV (table 4). However, 
the proportion reporting being aware of the HIVST inter-
vention arm was lower than expected after 12 months 
of ongoing distribution. Only 58.0% (1462/2520) of 
respondents in the HIVST intervention arm were aware 
of HIVST, compared with 28.3% (700/2474) in SOC arm. 
Of households in the HIVST arm who reported being 
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visited by CBDs, 75% (456/608) of respondents reported 
receiving an HIVST kit, and 75% of these (369/456) 
used the HIVST. Only 23.5% (585/2493) of respondents 
reporting HIVST during the intervention period.
Social harms and stigma
No social harms were identified during the study imple-
mentation period. There were no differences in self- 
reported IPV or in HIV stigma by arm. In adjusted anal-
yses, respondents in the HIVST were more likely to report 
there was pressure to test for their most recent HIV test 
regardless of testing mode (2.2% (43/1946) in interven-
tion and 1.3% (23/1802) in SOC).
DISCUSSION
We found no evidence that community- based distribution 
of HIVST by CBDs in community settings and at facili-
ties increased population levels of recent HIV testing or 
had an impact on secondary outcomes. Although HIVST 
Figure 1 CONSORT diagram showing flow of study participants. CONSORT, Consolidated Standards of Reporting Trials; 
HIVST, HIV self- testing.
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awareness was higher in the intervention arm, HIVST 
awareness remained low, and few individuals reported 
ever self- testing. Among the respondents visited at home 
by CBDs, most had accepted and used HIVST.
Other trials of community- based HIVST delivery 
have shown an impact on increasing population 
testing coverage. A companion STAR study of a similar 
HIVST intervention in rural Malawi found a 33% rela-
tive increase in population levels of recent testing after 
1 year of HIVST distribution, with a 76% increase among 
persons >20 years old and a 50% increase among men.23 
In Zambia, a cluster randomised trial of the door- to- door 
offer of HIVST as an option for HIV testing, nested in the 
HPTN 071 (PopART) trial of universal testing and treat-
ment, found a small but significant impact of the HIVST 
intervention on knowledge of HIV status.12 The effect of 
this nested intervention was driven by an impact among 
men, with no evidence of an effect among women. The 
Table 1 Characteristics of household survey respondents
HIVST intervention, N (%) SOC, N (%)
Baseline
Total 2433 2446
  Self- reported HIV positive status (n=1056) 42 (8.4) 44 (8.3)
  Ever tested for HIV† 1971 (82.2) 1918 (83.2)
  Tested for HIV within past 12 months‡ 1496 (63.3) 1457 (64.1)
Endline
Total households 1224 1206
Household characteristics
Assets index (no (%))§
  Lowest 345 (31.0) 397 (36.9)
  Second 386 (34.7) 367 (30.9)
  Highest 392 (34.2) 359 (32.2)
Individual characteristics 2528 2477
Age (mean (SD)) 32.7 (14.1) 33.8 (14.8)
Age group (no (%))
  16–19 years 354 (14.0) 363 (14.6)
  20–24 years 567 (22.4) 475 (19.2)
  25–29 years 439 (17.4) 404 (16.3)
  30–39 years 507 (20.1) 527 (21.3)
  40–49 years 315 (12.5) 321 (13.0)
  50–59 years 193 (7.6) 217 (8.8)
  60+ years 153 (6.0) 170 (6.9)
Male (no/%) 1048 (41.5) 970 (39.2)
Marital status (no/%)¶
  Married or living as married 1376 (54.5) 1383 (56.0)
  Never married 866 (34.3) 806 (32.6)
  Widowed/separated/divorced 282 (11. 2) 281 (11.4)
Education (no/%)**
  No or primary education 1275 (50.5) 1207 (48.8)
  Secondary incomplete 836 (33.1) 832 (33.6)
  Completed secondary or higher 416 (16.5) 437 (17.6)
*HIV status asked of 20% subsample only (n=511 in intervention areas and n=545 in comparison areas); 28 respondents declined to 
respond.
†Ever tested information missing for 176 respondents.
‡Tested in past 12 months; information missing for 243 respondents.
§Assets missing for 244 households and 442 respondents.
¶Marital status missing for 11 respondents.
**Education missing for two respondents.
HIVST, HIV self- testing; SOC, standard of care.
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offer of an HIVST to women for distribution to a partner 
absent at the time of the household visit contributed to 
this effect among men. In another STAR- supported study 
in rural Zimbabwe, a non- randomised comparison of 
areas with and without HIVST distribution campaigns 
found a 27% increase in ART initiations at local clinics 
during the campaign, suggesting that HIVST users in 
Zimbabwe were able to link successfully following a reac-
tive HIVST.31
This discrepancy in findings between our study and 
other evaluations of community HIVST distribution 
may be due to the low dose of intervention provided at 
population level, as levels of implementation are known 
to affect observed outcomes.32 33 In intervention clus-
ters, only 58% had heard of HIVST, and among these 
only 62% reported a CBD visiting their home. In the 
companion trial in Malawi, 88% of individuals sampled 
in the intervention arms had heard of HIVST compared 
with 29% in the control arms.23 Exposure to HIVST 
among area residents was thus lower than anticipated 
in intervention areas, leading to low HIVST uptake. 
Further, in some clusters few HIVST kits were distributed 
per capita, particularly in urban clusters. Taken together, 
these process measures suggest that HIVST may not have 
been accessible to all residents in intervention areas, 
hampering the ability to identify changes in the outcome.
Alternatively, an intervention may not show an impact 
because theories underlying the causal pathway linking 
the intervention with the expected outcome may be incor-
rect.30 Community- based distribution was expected to 
increase knowledge and acceptability of HIVST, remove 
barriers to accessing HTS and thereby increase coverage 
of HTS. In this study, CBDs distributed HIVST kits both 
door to door and in high- density areas. This distribution 
method may not have been as acceptable to community 
members as expected, so they may have been unlikely to 
learn about or receive HIVST from a CBD. Finally, as a 
novel technology at the time of the trial, more time may 
have been required for more individuals to consider 
HIVST as an acceptable way to test for HIV. As data to 
explore these specific domains were not collected at the 
time of the trial, we can only speculate whether accept-
ability affected the observed findings.
This intervention showed no impact on testing 
coverage among priority populations for HIVST: young 
people and men. HIVST has been shown to be highly 
acceptable among young people and men, including 
in Zambia.9 10 12 34 There is no evidence that this was 
different in this study, as nearly all survey respondents 
who received an HIVST kit reported using the test. 
However, in this intervention, HIVST may have been 
less accessible to key target subgroups than anticipated. 
Other models of HIVST distribution may be more 
effective at reaching these key subgroups. Secondary 
distribution models targeting the partners of antenatal 
care clients have been effective in increasing testing 
coverage,14 and secondary distribution strategies capi-
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among adolescents and other key populations.35–37 Work-
place distribution may also target men effectively, while 
distribution in family planning clinics, universities, clubs 
and other youth- friendly venues may make HIVST more 
accessible to adolescents.38 39 Community- led distribution 
strategies that include community members in the design 
and implementation of HIVST distribution programmes 
may also increase the acceptability and uptake of HIVST, 
particularly among otherwise underserved populations.40
This study has several limitations. Prevalence of recent 
testing for HIV at baseline was high in the study commu-
nities compared with estimates from the 2016 ZAMPHIA 
survey which the sample size was based on, leaving the 
study underpowered to detect differences in recent 
testing coverage. HIV testing and VMMC outcomes were 
measured using self- reported data, and are subject to 
misreporting, but were collected in the same manner in 
both arms and so are unlikely to have substantial bias. ART 
initiation was measured using clinic data and self- report. 
Although we were able to triangulate this outcome across 
data sources, we may have underestimated ART uptake as 
clinic catchment areas were larger than HIVST clusters, 
diluting clinic- level effects, and not all newly diagnosed 
PLHIV will have chosen their local clinic for HIV services 
leading to undercapture.
While HIVST has potential to increase testing uptake 
among populations unreached by currently available 
HTS, broad community- based distribution of HIVST was 
not successful in increasing testing coverage at popula-
tion level in Zambia. HIVST distribution in high- density 
areas, door to door and in health facilities increased 
awareness of HIVST, but levels of ever HIVST remained 
low in intervention arm. Rigorous monitoring and eval-
uation of the distribution in real time, with distribution 
incentives promoting the identification of new testers 
and populations less likely to otherwise test, may have 
improved the reach and dose of the intervention and 
increased its effectiveness.
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